Investigational drug · Phase 3
EU-sourced Keytruda
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "EU-sourced Keytruda"
First trial start
2024
Dec 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EU-sourced Keytruda", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Squamous Non-Small Cell Lung Cancer
- Non Squamous Non Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "EU-sourced Keytruda" as an intervention, largest first.
- A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung CancerPivotal-lookingNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT06847334 · 772 participants (planned) · Start Apr 27, 2025 · Primary completion Apr 9, 2027
Drug: HLX17; US-sourced Keytruda® and 1 more · For: Non-Squamous Non-Small Cell Lung Cancer
- A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)Pivotal-lookingActive, not recruiting
mAbxience Research S.L.Industry
NCT06687369 · 726 participants (planned) · Start Dec 30, 2024 · Primary completion Aug 31, 2026
Drug: MB12 (Proposed Pembrolizumab Biosimilar); EU-sourced Keytruda® and 4 more · For: Non Squamous Non Small Cell Lung Cancer
Sites: Yerevan, Armenia; Sarajevo, Bosnia and Herzegovina; Tuzla, Bosnia and Herzegovina · 173 sites in all
- A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based ChemotherapyPivotal-lookingActive, not recruiting
Samsung Bioepis Co., Ltd.Industry
NCT06268613 · 163 participants · Start Jan 16, 2024 · Primary completion Feb 19, 2026
Drug: SB27; EU sourced Keytruda and 1 more · For: Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage IIIA
Sites: Gdansk, Poland; Otwock, Poland; Ansan, South Korea · 24 sites in all
Bio-Thera SolutionsIndustry
NCT06111196 · 59 participants · Start Nov 5, 2023 · Primary completion Jun 11, 2024
Drug: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection; Pembrolizumab injection · For: Healthy Male Subjects
Sites: Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-Squamous Non-Small Cell Lung Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- AumolertinibSHR-A2009, HS-10296Phase 37 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Advanced Solid Tumors
- US-sourced KeytrudaPhase 32 trials
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer
- VEGF bispecific antibodyPhase 32 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Squamous Non-small-cell Lung Cancer, Non-squamous Non-small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.